Company news

Tonix Pharmaceuticals Holding Corp. news in 2019

Tonix Pharmaceuticals Holding Corp.'s news releases, calls and decks from 2019, newest first.

View company

Tonix Pharmaceuticals Announces Plan to Develop TNX-601 CR Tablets for Once-Daily Treatment of Major Depressive Disorder, in Addition to PTSD, After Successful Completion of Phase 1 Pharmacokinetic Study

December 15, 2019

Tonix Pharmaceuticals Announces New European Patent for the Composition and Formulation of TNX-102 SL

December 10, 2019

Tonix Pharmaceuticals Enrolls First Patient in Phase 3 RELIEF Study of TNX-102 SL for the Management of Fibromyalgia

December 9, 2019

Tonix Pharmaceuticals Regains Compliance with NASDAQ Minimum Bid Price Requirement

December 2, 2019

Tonix Pharmaceuticals Announces Receipt of FDA Official Minutes from Breakthrough Therapy Type B Clinical Guidance Meeting for Tonmya® as a Potential New Treatment for PTSD

November 25, 2019

Tonix Pharmaceuticals Announces Initiation of the Phase 3 RELIEF Study of TNX-102 SL for the Management of Fibromyalgia

November 20, 2019

Tonix Pharmaceuticals Completes Pre-IND Meeting with FDA for TNX-102 SL as a Clinical Candidate for Alcohol Use Disorder

November 19, 2019

Tonix Pharmaceuticals Prices $9.0 Million Public Offering

November 14, 2019

Tonix Pharmaceuticals Reports Third Quarter 2019 Financial Results and Operational Highlights

November 7, 2019

Tonix Pharmaceuticals Announces 12-Week Primary Endpoint and Addition of Adaptive Design Features in the Currently-Enrolling Phase 3 RECOVERY Study of Tonmya® for PTSD, Following FDA Meeting

November 3, 2019

Tonix Pharmaceuticals Announces 1-for-10 Reverse Stock Split

October 30, 2019

Tonix Pharmaceuticals Announces Issuance of U.S. Patent for Crystalline Tianeptine Oxalate Salt, the Active Ingredient of TNX-601

October 22, 2019

Tonix Pharmaceuticals Joins the Alliance for Biosecurity

October 14, 2019

Tonix Pharmaceuticals Announces that the European Patent Office Opposition Division Has Upheld Its Patent for the Use of the Active Ingredient in TNX-102 SL, Cyclobenzaprine, for the Treatment of PTSD

October 6, 2019

Tonix Pharmaceuticals Announces Completion of Long-Term Exposure Studies in Participants with PTSD to Evaluate the Tolerability of TNX-102 SL 5.6 mg

October 2, 2019

Tonix Pharmaceuticals Announces Licensing Agreement with Columbia University for the Development of Recombinant Trefoil Family Factor 2 (rTFF2), or TNX-1700, for the Treatment of Gastric and Pancreatic Cancers

September 15, 2019

Tonix Pharmaceuticals Plans to Expand TNX-102 SL Phase 3 Program Beyond PTSD to Include Fibromyalgia

April 3, 2019

Decks in 2019